Joel Beatty
Stock Analyst at Baird
(4.47)
# 307
Out of 4,981 analysts
197
Total ratings
48.1%
Success rate
25.42%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Maintains: Outperform | $50 → $67 | $37.16 | +80.30% | 3 | Sep 9, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $2.69 | +123.05% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $12.66 | -28.91% | 6 | Jul 8, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $110 → $145 | $135.22 | +7.23% | 7 | Jun 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $23.61 | +31.30% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $19.00 | +26.32% | 5 | May 16, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $756.38 | -10.10% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $14.19 | +104.37% | 2 | May 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $70 → $66 | $61.11 | +8.00% | 15 | May 7, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $167 → $155 | $126.16 | +22.86% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $118.42 | +36.80% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $26.97 | +52.02% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $3.93 | +154.45% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $9.44 | +69.49% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $12.36 | +29.50% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $37.71 | +93.61% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $19.97 | +60.24% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $48.10 | +55.93% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $11.65 | -5.58% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.64 | +326.83% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $54.09 | +20.17% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $30.31 | +137.55% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $1.62 | +14,714.81% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.27 | +254.33% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $9.05 | +176.24% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.30 | +2,914.07% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $15.55 | +80.06% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.01 | +696.02% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.83 | -31.69% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.59 | +2,667.30% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $29.72 | +95.15% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $24.63 | -2.56% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $17.32 | +3.93% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.05 | +192.68% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.00 | +460.00% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $465.89 | -62.44% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.51 | +210.42% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $17.39 | +521.05% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $63.16 | +23.50% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $9.87 | +913.17% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $15.01 | +699.47% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $3.26 | +13,703.68% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.84 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $7.98 | +87.97% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.44 | +27,448.21% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $8.19 | +131.99% | 3 | Nov 10, 2017 |
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50 → $67
Current: $37.16
Upside: +80.30%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $2.69
Upside: +123.05%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $12.66
Upside: -28.91%
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110 → $145
Current: $135.22
Upside: +7.23%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $23.61
Upside: +31.30%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $19.00
Upside: +26.32%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $756.38
Upside: -10.10%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $14.19
Upside: +104.37%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $61.11
Upside: +8.00%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $126.16
Upside: +22.86%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $118.42
Upside: +36.80%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $26.97
Upside: +52.02%
Mar 25, 2025
Maintains: Outperform
Price Target: $13 → $10
Current: $3.93
Upside: +154.45%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $9.44
Upside: +69.49%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $12.36
Upside: +29.50%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $37.71
Upside: +93.61%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $19.97
Upside: +60.24%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $48.10
Upside: +55.93%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $11.65
Upside: -5.58%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.64
Upside: +326.83%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $54.09
Upside: +20.17%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $30.31
Upside: +137.55%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $1.62
Upside: +14,714.81%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.27
Upside: +254.33%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $9.05
Upside: +176.24%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.30
Upside: +2,914.07%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $15.55
Upside: +80.06%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $2.01
Upside: +696.02%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.83
Upside: -31.69%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.59
Upside: +2,667.30%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $29.72
Upside: +95.15%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $24.63
Upside: -2.56%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $17.32
Upside: +3.93%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.05
Upside: +192.68%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.00
Upside: +460.00%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $465.89
Upside: -62.44%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.51
Upside: +210.42%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $17.39
Upside: +521.05%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $63.16
Upside: +23.50%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $9.87
Upside: +913.17%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $15.01
Upside: +699.47%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $3.26
Upside: +13,703.68%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $2.84
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $7.98
Upside: +87.97%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.44
Upside: +27,448.21%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $8.19
Upside: +131.99%